CDEK by Data4ThePeople
Sign in Sign up
← All organizations

Novellus Therapeutics

For profit

Also known as: Fore Biotherapeutics

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 2

First clinical trial

Nov 1, 2022

Last known activity

Nov 15, 2024

Acquired by Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics → IRX Therapeutics → Brooklyn Immunotherapeutics on Jun 17, 2021

Timeline

2010s

  1. Jun 1, 2014

    Novellus Therapeutics— Founded

  2. Nov 7, 2018

    Brooklyn Immunotherapeutics— Now

2020s

  1. Jun 17, 2021

    Brooklyn Immunotherapeutics— Acquired By

Drugs by trial phase (2 distinct, 3 trials)

Phase 2 (2 own, 0 via acquisition)

Recent trials (4)

Details

Founded
Cambridge, MA, US Jun 1, 2014
Last known activity
Nov 15, 2024